Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 With Background Treatment in Subjects With Lupus Nephritis
NCT03943147 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 With Background Treatment in Subjects With Lupus Nephritis
- Lead sponsor
- Bristol-Myers Squibb
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- July 15, 2019
- Completion date
- September 17, 2021
- Enrollment
- 16 (actual)
- Sites
- 100
Conditions
As the registry lists them; a condition with its own page is linked.